Absci Stock (NASDAQ:ABSI)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.38

52W Range

$2.24 - $7.39

50D Avg

$4.87

200D Avg

$3.59

Market Cap

$1.01B

Avg Vol (3M)

$4.88M

Beta

2.46

Div Yield

-

ABSI Company Profile


Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

156

IPO Date

Jul 22, 2021

Website

ABSI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 21
Collaborative Revenue$136.00K
Technology Development Revenue$592.00K

Fiscal year ends in Dec 25 | Currency in USD

ABSI Financial Summary


Dec 25Dec 24Dec 23
Revenue$2.80M$4.53M$5.72M
Operating Income$-124.72M$-108.89M$-115.52M
Net Income$-115.18M$-103.11M$-110.57M
EBITDA$-112.98M$-94.10M$-79.68M
Basic EPS$-0.84$-0.94$-1.20
Diluted EPS$-0.84$-0.94$-1.20

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q4 25Mar 24, 26 | 4:30 PM
Q3 25Nov 12, 25 | 4:30 PM
Q2 25Aug 13, 25 | 4:30 PM

Peer Comparison


TickerCompany
RGNXREGENXBIO Inc.
GOSSGossamer Bio, Inc.
PRTAProthena Corporation plc
MGTXMeiraGTx Holdings plc
VSTMVerastem, Inc.
VTYXVentyx Biosciences, Inc.
ERASErasca, Inc.
OLMAOlema Pharmaceuticals, Inc.
CRVSCorvus Pharmaceuticals, Inc.
MLTXMoonLake Immunotherapeutics